Lupus (SLE) trials in Poland

In Poland 25 Also abroad 354

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól, Poznan, Warsaw, Wroclaw
Age
18 years to 70 years
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Bydgoszcz, Bytom, Warsaw, Wroclaw
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Bytom, Cracow, Lublin, Malbork, Rzeszow, Rzeszów, Warszawa, Zamość
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Cracow, Lodz, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Gdansk
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Bydgoszcz, Bytom, Cracow, Katowice, Nadarzyn, Nowa Sol, Plonsk, Poznan, Warsaw
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Cracow, Janki, Katowice, Lublin, Poznan, Warsaw, Wroclaw
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
Phase 2Not yet taking people in Poland
A Trial of LAD603 in Patients with Systemic Lupus Erythematosus
Where
Cracow, Janki, Poznan, Warsaw
Age
18 years and over
People
20 worldwide
Run by
Almirall S.A.
See details and how to join2026-527200-24-00 · EU 2026-527200-24-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Bydgoszcz, Cracow, Poznan, Warsaw, Wrocław
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 3Not yet taking people in Poland
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bydgoszcz, Cracow, Katowice, Kielce, Ozarowice, Warsaw
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Where
Cracow, Warsaw
Age
18 years to 70 years
People
24 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Bialystok, Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Warsaw, Wroclaw
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Not yet taking people in Poland
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Bydgoszcz, Krakow, Poznan
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Bialystok, Bydgoszcz, Bytom, Cracow, Malbork, Poznan, Warsaw
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Bydgoszcz, Cracow, Częstochowa, Katowice, Lodz, Lublin, Nadarzyn, Nowa Sol, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
113 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Lodz, Warsaw, Wroclaw
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 1Taking people
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
Where
Bydgoszcz, Cracow, Katowice, Poznan, Warsaw
Age
18 years and over
People
13 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526171-32-00 · EU 2026-526171-32-00
Phase 3Taking people
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
Where
Bialystok, Bydgoszcz, Cracow, Katowice, Lublin, Nadarzyn, Poznan, Warsaw
Age
18 years and over
People
147 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00
Phase 3Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Where
Bialystok, Bydgoszcz, Cracow, Częstochowa, Katowice, Lodz, Lublin, Poznan, Poznań, Wrocław
Age
18 years to 75 years
People
680 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00
Phase 3Taking people
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Where
Cracow, Katowice, Lodz, Opole, Poznan, Swiecie, Warsaw, Wroclaw
Age
18 years to 75 years
People
300 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT07201129 · EU 2025-522984-14-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Bytom, Gdansk, Gliwice, Lodz
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Cracow, Poznan, Warsaw
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 1Taking people
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Where
Bialystok, Bydgoszcz, Cracow, Poznan, Warsaw, Wroclaw
Age
18 years to 65 years
People
142 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06576271 · EU 2024-514186-18-00
Phase 3Not yet taking people in Poland
Clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)
Where
Gdansk, Katowice-Ochojec, Krakow, Warsaw
Age
18 years and over
People
90
Run by
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
See details and how to join2024-517753-27-01 · EU 2024-517753-27-01